(HealthDay News) – The pneumococcal conjugate vaccine containing 10 serotype-specific polysaccharides conjugated to Haemophilus influenza protein D, tetanus toxoid, and diphtheria toxoid as the carrier proteins (PHiD-CV10) is effective against invasive pneumococcal disease, including in infants using a 2+1 schedule, according to a study published online Nov. 16 in The Lancet.
Arto A. Palmu, MD, from the National Institute for Health and Welfare in Tampere, Finland, and colleagues conducted a cluster-randomized trial in which children aged <19 months received PHiD-CV10 in 52 clusters or hepatitis vaccines as control in 26 clusters. A 3+1 or a 2+1 vaccination schedule was used in infants <7 months at the first vaccination. A 2+1 schedule was used in children aged 7–11 months, and those 12–18 months of age received a two-dose schedule.
The researchers found that, of the 30,528 participants assessed for the primary objective, 13 culture-confirmed vaccine-type cases of invasive pneumococcal disease were detected (none in the PHiD-CV10 3+1 group; one in the PHiD-CV10 2+1 group; and 12 in the control groups). For PHiD-CV10 3+1, the vaccine effectiveness was estimated at 100%, and 92% effectiveness was estimated for PHiD-CV10 2+1. In combined PHiD-CV10 infant cohorts there were two cases of any culture-confirmed invasive disease, compared with 14 in the corresponding control cohorts (vaccine effectiveness 93%). Seven cases of invasive disease were reported in catch-up cohorts, all of which were in the control group.
“This nationwide trial showed high PHiD-CV10 effectiveness against invasive pneumococcal disease when given in different schedules,” the authors write. “For the first time, effectiveness of a 2+1 schedule in infants was confirmed in a clinical trial.”
Several authors disclosed financial ties to pharmaceutical companies, including GlaxoSmithKline, which in part funded the study.
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)